NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement
About NLS Pharmaceutics Ltd. ZURICH, SWITZERLAND / ACCESSWIRE / January 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. The Company has now successfully resolved both outstanding Nasdaq compliance issues.
瑞士苏黎世/ACCESSWIRE/2023年1月25日/致力于为罕见和复杂的中枢神经系统疾病患者发现和开发创新疗法的瑞士临床期生物制药公司纳斯达克制药有限公司(纳斯达克股票代码：NLSP)(以下简称“公司”)今天宣布，它已收到纳斯达克股票市场有限责任公司(以下简称“纳斯达克”)听证会小组(“小组”)的一封通知信，通知公司公司已重新遵守纳斯达克上市规则第5550(B)(1)条，该规则要求上市公司维持至少2500,000美元的股东权益。该公司现在已经成功解决了这两个悬而未决的纳斯达克合规问题。
As previously announced, on April 1, 2022, NLS was first notified by Nasdaq of its failure to comply with Nasdaq Listing Rule 5550(b)(1). As reported on November 14, 2022, following an appeal by NLS, the Panel granted the Company's request to continue its listing on Nasdaq and further requested that the Company demonstrate compliance with Listing Rule 5550(b)(1) no later than February 28, 2023.
如前所述，2022年4月1日，不良资产管理公司首次接到纳斯达克的通知，称其未能遵守纳斯达克上市规则第5550(B)(1)条。据2022年11月14日报道，在NLS提出上诉后，陪审团批准了该公司继续在纳斯达克上市的请求，并进一步要求该公司至迟于2023年2月28日证明遵守了上市规则第5550(B)(1)条。
On January 24, 2023, the Panel confirmed the Company's compliance with the previously communicated conditions and determined that the Company regained compliance with Listing Rule 5550(b)(1). Accordingly, the Panel has determined to continue the listing of the Company's securities on Nasdaq and considers this matter closed.
2023年1月24日，专家小组确认该公司遵守了先前传达的条件，并确定该公司重新遵守上市规则第5550(B)(1)条。因此，小组决定继续将该公司的证券在纳斯达克上市，并认为此事已经结束。
About NLS Pharmaceutics Ltd.
关于NLS制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS制药有限公司(纳斯达克代码：NLSP)是一家全球开发期生物制药公司，与世界级合作伙伴和国际公认的科学家网络合作，专注于为患有罕见和复杂的中枢神经系统疾病的患者发现和开发创新疗法，这些患者的医疗需求尚未得到满足。NLS总部设在瑞士，成立于2015年，由一支经验丰富的管理团队领导，该团队在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
有关更多信息，请访问：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投资者和媒体)
NLS制药有限公司。
+1 239.682.8500
邮箱：ml@nls-pharma.com
###
###
SOURCE: NLS Pharmaceutics AG
资料来源：NLS制药公司